Equine protozoal myeloencephalitis.
Recent advances in the understanding of the parasite life cycle, epidemiology, clinical signs, diagnosis, treatment, and prevention of EPM are reviewed. The NAHMS Equine '98 study and a controlled retrospective study from The Ohio State University College of Veterinary Medicine identified a number of risk factors associated with development of the disease. The national annual incidence of EPM was 1% or less depending on the primary use of the animals. Increased disease risk was associated with age (1-5 and > 13 years of age), season (lowest in winter months and increasing with ambient temperature), previous stressful events, the presence of opossums, the use of nonsurface water drinking systems, and failure to restrict wildlife access to feed. Horses that received treatment were 10 times more likely to improve, and those that improved were 50 times more likely to survive. A number of recent studies confirmed that horses can be experimentally infected with S. neurona; however, large numbers of sporocysts are apparently necessary to achieve infection, and clinical signs and abnormal CNS histology are only seen inconsistently. Results suggest that CNS infection and positive CSF immunoblot findings may be transient phenomena among naturally infected horses. Although immunosuppression may be involved in the development of EPM, some element of the immune response seems to be necessary for the development of clinical signs. Use of the standard immunoblot test for the detection of anti-S. neurona antibodies in CSF continues to provide the most useful adjunct to a detailed neurologic examination for the diagnosis of EPM. Test sensitivity and specificity were 89% in 295 horses euthanatized because of neurologic disease, of which 123 were confirmed cases of EPM. The PPV was 85%, and the NVP was 92%. A number of promising new EPM treatments are under investigation. In addition to standard SDZ/PYR therapy, toltrazuril, ponazuril, diclazuril, and NTZ have shown promise as possible alternatives.
MacKay
R J
RJ
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.
Granstrom
D E
DE
Saville
W J
WJ
Reed
S M
SM
D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D003048:Coccidiosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary; D004196:Disease Outbreaks / Q000662:veterinary*; D004679:Encephalomyelitis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D006734:Horse Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D006736:Horses; D018688:Neospora / Q000276:immunology; D012522:Sarcocystis / Q000276:immunology; D012523:Sarcocystosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D012621:Seasons
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents